Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' Consolidated Net Income rose 818.75% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10616.1%. This contributed to the annual value of -$14.0 million for FY2024, which is 8739.19% up from last year.
  • Heron Therapeutics' Consolidated Net Income amounted to -$4.1 million in Q3 2025, which was up 818.75% from -$1.6 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Consolidated Net Income peaked at $4.2 million during Q4 2024, and registered a low of -$62.9 million during Q1 2022.
  • Moreover, its 5-year median value for Consolidated Net Income was -$24.9 million (2023), whereas its average is -$27.2 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first tumbled by 2074.11% in 2022, then surged by 16573.57% in 2025.
  • Over the past 5 years, Heron Therapeutics' Consolidated Net Income (Quarter) stood at -$53.5 million in 2021, then surged by 61.98% to -$20.4 million in 2022, then surged by 49.79% to -$10.2 million in 2023, then skyrocketed by 140.83% to $4.2 million in 2024, then plummeted by 198.08% to -$4.1 million in 2025.
  • Its last three reported values are -$4.1 million in Q3 2025, -$1.6 million for Q2 2025, and $3.2 million during Q1 2025.